ARS Pharmaceuticals

New Capabilities

As of May 2026: neffy expanding internationally; EMA positive opinion issued for pediatric use in Europe

For nearly four decades, Americans facing life-threatening allergic reactions had exactly one option: stab themselves with a needle. The EpiPen and its competitors delivered epinephrine effectively, but needle phobia kept roughly 30% of patients from using their prescribed devices during emergencies—contributing to preventable deaths. Now the needle era is ending.

Updated May 23